10-13-2010: MorphoSys AG and Proteros Biostructures announced that they have been awarded a grant by the German Federal Ministry of Education and Research, BMBF. The funding of approximately EUR 850,000 supports both companies in establishing a new technology platform for efficient structural characterization of antibody-antigen-complexes. MorphoSys will provide relevant antigen and antibody molecules, Proteros will provide advanced x-ray technology and computational chemistry know-how. The high resolution access to antibody-antigen-complex structures is expected to allow a faster and more efficient engineering of therapeutic antibodies. The program is part of Munich's biotechnology initiative "m4 - Personalized Medicine and Targeted Therapies - A New Dimension in Drug Development in the Munich Region", which this year received Leading-Edge Cluster status in a German government funding competition.
In the first project, the two companies will analyze MorphoSys's proprietary clinical anti-inflammatory antibody MOR103 and the binding properties to its corresponding antigen GM-CSF. MOR103 is a fully human HuCAL antibody directed against GM-CSF (granulocyte macrophage-colony stimulating factor), being developed in the area of inflammatory diseases, for example rheumatoid arthritis. Due to its diverse functions in the immune system, GM-CSF can be considered a target for a broad spectrum of anti-inflammatory therapies. The program is currently being evaluated in a European clinical phase 1b/2a trial in patients with active rheumatoid arthritis.
"Early clarification of the precise interaction between antibody and antigen is very valuable information in drug discovery, as it can help in identifying the most promising lead candidate or in generating improved follow-up compounds by directed molecular evolution," commented Dr Marlies Sproll, Chief Scientific Officer of MorphoSys AG. "Within the research program we'll bring together MorphoSys's antibody expertise and Proteros's structure solution know-how to tackle challenges in crystallizing whole IgG molecules."
"The analysis of antibody-antigen interaction at atomic resolution efficiently guides the further evolution of antibodies," commented Dr. Torsten Neuefeind, CEO of Proteros. "In the joint program, a technology platform will be developed which combines the strengths of combinatorial biology and rational structure guided approaches".
Contact / Request information
Request further information free of charge:
MorphoSys and Proteros Biostructures Receive Research Grant
MorphoSys AG and Proteros Biostructures announced that they have been awarded a grant by the German Federal Ministry of Education and Research, BMBF. The funding of approximately EUR 850,000 supports both companies in establishing a new technology platform for efficient structural character ... more
MorphoSys Announces Acquisition of Sloning
MorphoSys AG announced the acquisition of Sloning BioTechnology GmbH. The transaction will make MorphoSys the sole source of Sloning's state-of-the-art Slonomics technology, which improves the assembly and quality of protein libraries. By integrating Slonomics into its existing antibody tec ... more
MorphoSys Strengthens Patent Position on its Core HuCAL Technology in Europe
MorphoSys AG announced that the European Patent Office has granted a European divisional patent stemming from MorphoSys's base HuCAL (Human Combinatorial Antibody Library) patent family, providing extended protection for the Company's core technology. The new patent (EP1143006) captures HuC ... more
As one of the leading public biotech companies in Europe, we are committed to developing the medicines of the future. Building on our portfolio of innovative antibody technologies, we are actively pursuing new therapeutic approaches in close collaboration with the world‘s foremost pharmaceu ... more
Proteros has relocated to a tailor-made facility in Martinsried
Proteros biostructures GmbH is further extending its business capacities by moving into a new building in Munich-Martinsried, one of the leading Biotech locations in Germany. After a two-year planning period, Proteros has reached an important milestone in itsdevelopment by centralizing all ... more
Nimbus Discovery and Proteros enter into multi-target X-ray protein crystallography collaboration
Proteros Biostructures GmbH announced that it has entered into a strategic collaboration with Nimbus Discovery, LLC to deliver X-ray protein crystal structures for multiple targets.Under the agreement, Proteros will provide structures from its Gallery Structure list, an ever growing catalog ... more
Proteros Biostructures GmbH (Proteros) announced that it has entered into a service agreement with CHDI Foundation, Inc. (CHDI), under which Proteros will provide structure-based drug discovery services to CHDI. Proteros will apply its integrated discovery platform including proprietary X-r ... more
MorphoSys and Proteros Biostructures Receive Research Grant
MorphoSys AG and Proteros Biostructures announced that they have been awarded a grant by the German Federal Ministry of Education and Research, BMBF. The funding of approximately EUR 850,000 supports both companies in establishing a new technology platform for efficient structural character ... more
The NanoCare Project has gained new knowledge about the effects of nanomaterials on health and on the environment. Dr. Peter Nagler, head of Innovation Management for Evonik’s Chemistry Business Area, said that the project, sponsored by the Federal Ministry of Education and Research, would ... more
Novel German Research Alliance to Detect Precursors of Colorectal Cancer
The German Federal Ministry of Education and Research will fund a clinical research project for the early detection of colorectal cancer, to be realized by an alliance of Scientists from the 2nd Medical Clinic of the University vHospital rechts der Isar at the Munich Technical University, t ... more
About analytica-world.com
analytica-world.com is the industry portal of the international trade fair analytica, which is organized by Messe München. It features useful information about markets, trends and innovations. It is operated by CHEMIE.DE, one of analytica's official sales partners.
Advertising at analytica-world.com
Our advertising formats support you in getting your message across to a clearly defined target audience.
The global network of analytica trade fairs:
